Evidence-Based Treatment on Nasal Polyposis

  • Bengü Çobanoğlu
  • Mehmet İmamoğlu
  • Luisa Bellussi


Nasal polyps (NPs) affect approximately 4% of the population (0.5–4%) and are mass lesions of the nasal cavity and are caused by inflammation. Typical symptoms are postnasal drip, anosmia, obstruction, rhinorrhea, and facial pain. The cause of NPs is not known; however, they have been associated with asthma, cystic fibrosis, allergies, fungus, multiple infections, and aspirin. Recurrence has been observed in approximately 10% of patients. In the past two decades, increased knowledge of NP pathobiology has opened new avenues for therapeutic intervention, which has been focused on S. aureus and fungi as well as other molecular pathways as potential targets. In particular, investigation and knowledge of chronic inflammation in NP has been essential to develop novel pharmacological approaches. NPs have been reported to occur in between 0.5% and 4% of the population, with the majority being asymptomatic in older patients. Controlling NP encompasses the use of both medication and sometimes surgery. Evidence suggests that corticosteroids are a primary therapy and prevent recurrence; however, the use of these drugs has multiple adverse effects and is not good as a long-term treatment option. Therefore, new therapies that have less side effects and long-term treatment are being investigated. This chapter summarizes the current knowledge for the treatment of NPs and the current and future methodologies that are/will be used to effectively manage medical intervention.


Nasal polyps Treatment Evidence based Medication Surgery 


  1. 1.
    RNewton J, Ah-See KW. A review of nasal polyposis. Ther Clin Risk Manag. 2008;4(2):507–12.Google Scholar
  2. 2.
    Rajguru R. Nasal polyposis: current trends. Ind J Otolaryngol Head Neck Surg. 2014;66(Suppl 1):16–21.Google Scholar
  3. 3.
    Davis LJ, Kita H. Pathogenesis of chronic rhinosinusitis: role of airborne fungi and bacteria. Immunol Allergy Clin N Am. 2004;24:59–73.Google Scholar
  4. 4.
    Naclerio RM, Pinto J, Baroody F. Evidence-based approach to medical and surgical treatment of nasal polyposis. J Allergy Clin Immunol. 2013;132:6.Google Scholar
  5. 5.
    Wang DY. Significance of susceptible gene expression profiles in nasal polyposis. Clin Exp Otorhinolaryngol. 4:177–83.PubMedCentralGoogle Scholar
  6. 6.
    Fajardo-Dolci G, Solorio-Abreu J, Romero-Alvarez JC, Zavaleta-Villa B, Cerezo-Camacho O, Jimenez-Lucio R, et al. DQA1 and DQB1 association and nasal polyposis. Otolaryngol Head Neck Surg. 2006;135(2):243–7.PubMedGoogle Scholar
  7. 7.
    Ramanathan M Jr, Lee WK, Spannhake EW, Lane AP. Th2 cytokines associated with chronic rhinosinusitis with polyps down-regulate the antimicrobial immune function of human sinonasal epithelial cells. Am J Rhinol. 2008;22(2):115–21.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Foreman A, Psaltis AJ, Tan LW, Wormald PJ. Characterization of bacterial and fungal biofilms in chronic rhinosinusitis. Am J Rhinol Allergy. 2009;23(6):556–61.PubMedGoogle Scholar
  9. 9.
    Kilty SJ, Desrosiers MY. The role of bacterial biofilms and the pathophysiology of chronic rhinosinusitis. Curr Allergy Asthma Rep. 2008;8(3):227–33.PubMedGoogle Scholar
  10. 10.
    Weschta M, Rimek D, Formanek M, Polzehl D, Riechelmann H. Local production of Aspergillus fumigatus specific immunoglobulin E in nasal polyps. Laryngoscope. 2003;113:1798–802.PubMedGoogle Scholar
  11. 11.
    Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol. 2012;22(1):1–12.PubMedGoogle Scholar
  12. 12.
    Bachert C, Robillard T. Management of nasal polyposis. B-ENT. 2005;1(Suppl. 1):77–86.PubMedGoogle Scholar
  13. 13.
    Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, Cohen N, Cervin A, Douglas R, Gevaert P, Georgalas C, Goossens H, Harvey R, Hellings P, Hopkins C, Jones N, Joos G, Kalogjera L, Kern B, Kowalski M, Price D, Riechelmann H, Schlosser R, Senior B, Thomas M, Toskala E, Voegels R, Wang de Y, Wormald PJ. European Position Paper on Rhinosinusitis and Nasal Polyps 2012.Google Scholar
  14. 14.
    Allen DB. Systemic effects of intranasal steroids: an endocrinologist’s perspective. J Allergy Clin Immunol. 2000;106:S179–90.PubMedGoogle Scholar
  15. 15.
    Demoly P. Safety of intranasal corticosteroids in acute rhinosinusitis. Am J Otolaryngol. 2008;29:403–13.PubMedGoogle Scholar
  16. 16.
    Zitt M, Kosoglou T, Hubbell J. Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf. 2007;30:317–26.PubMedGoogle Scholar
  17. 17.
    Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf. 2000;23:11–33.Google Scholar
  18. 18.
    Tos M, Svendstrup F, Arndal H, et al. Efficacy of an aqueous and a powder formulation of nasal budesonide compared in patients with nasal polyps. Am J Rhinol. 1998;12:183–9.PubMedGoogle Scholar
  19. 19.
    Lund VJ, Flood J, Sykes AP, et al. Effect of fluticasone in severe polyposis. Arch Otolaryngol Head Neck Surg. 1998;124:513–8.PubMedGoogle Scholar
  20. 20.
    Penttila M, Poulsen P, Hollingworth K, et al. Dose related efficacy and tolerability of fluticasone propionate nasal drops 400 microg once daily and twice daily in the treatment of bilateral nasal polyposis: a placebo-controlled randomized study in adult patients. Clin Exp Allergy. 2000;30:94–102.PubMedGoogle Scholar
  21. 21.
    Stjarne P, Mosges R, Jorissen M, et al. A randomized controlled trial of mometasone furoate nasal spray for the treatment of nasal polyposis. Arch Otolaryngol Head Neck Surg. 2006;132:179–85.PubMedGoogle Scholar
  22. 22.
    Stjarne P, Blomgren K, Caye-Thomasen P, et al. The efficacy and safety of once-daily mometasone furoate nasal spray in nasal polyposis: a randomized, double-blind, placebo controlled study. Acta Otolaryngol. 2006;126:606–12.PubMedGoogle Scholar
  23. 23.
    Lildholdt T, Rundcrantz H, Bende M, Larsen K. Glucocorticoid treatment for nasal polyps. The use of topical budesonide powder, intramuscular betamethasone, and surgical treatment. Arch Otolaryngol Head Neck Surg. 1997;123:595–600.PubMedGoogle Scholar
  24. 24.
    Keith PK, Conway M, Evans S, et al. Nasal polyps: effects of seasonal allergen exposure. J Allergy Clin Immunol. 1994;93(3):567–74.PubMedGoogle Scholar
  25. 25.
    Haye R, Aanesen JP, Burtin B, et al. The effect of cetirizine on symptoms and signs of nasal polyposis. J Laryngol Otol. 1998;112:1042–6.PubMedGoogle Scholar
  26. 26.
    Wallwork B, Coman W, Feron F, et al. Clarithromycin and prednisolone inhibit cytokine production in chronic rhinosinusitis. Laryngoscope. 2002;112(10):1827–30.PubMedGoogle Scholar
  27. 27.
    Cervin A. The anti-inflammatory effect of erythromycin and its derivatives, with special reference to nasal polyposis and chronic sinusitis. Acta Otolaryngol. 2001;121(1):83–92.PubMedGoogle Scholar
  28. 28.
    Yamada T, Fujieda S, Mori S, et al. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am J Rhinol. 2000;14(3):143–8.PubMedGoogle Scholar
  29. 29.
    Ichimura K, Shimazaki Y, Ishibashi T, Higo R. Effect of new macrolide roxithromycin upon nasal polyps associated with chronic sinusitis. Auris Nasus Larynx. 1996;23:48–56.PubMedGoogle Scholar
  30. 30.
    Smith TL, Sautter NB. Is montelukast indicated for treatment of chronic rhinosinusitis with polyposis? Laryngoscope. 2014;124.PubMedGoogle Scholar
  31. 31.
    Modrzynski M, Zavisza E, Rapiejko P. Zafirlukast in treatment of nasal polyposis in patients with aspirin intolerant bronchial asthma-preliminary report. Pol Merkur Lekarski. 2002;12(69):224–7.PubMedGoogle Scholar
  32. 32.
    Schaper C, Noga O, Koch B, et al. Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis. J Investig Allergol Clin Immunol. 2011;21:51–8.Google Scholar
  33. 33.
    Ulualp SO, Sterman BM, Toohill RJ. Antileukotriene therapy for the relief of sinus symptoms in aspirin triad disease. Ear Nose Throat J. 1999;78(8):604–6, 608, 613 102.PubMedGoogle Scholar
  34. 34.
    Ragab S, Parikh A, Darby YC, et al. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy Immunol. 2001;166(3):1457–61.Google Scholar
  35. 35.
    Vuralkan E, Saka C, Akin I, et al. Comparison of montelukast and mometason furoat in the prevention of recurrent nasal polyps. Ther Adv Respir Dis 2012.Google Scholar
  36. 36.
    Pauli C, Fintelmann R, Klemens C, et al. Polyposis nasi improvement in quality of life by the influence of leukotriene receptor antagonists. Laryngorhinootologie. 2007;86(4):282–6.PubMedGoogle Scholar
  37. 37.
    Stewart RA, Ram B, Hamilton G, Weiner J, Kane KJ. Montelukast as an adjunct to oral and inhaled steroid therapy in chronic nasal polyposis. Otolaryngol Head Neck Surg. 2008;139(5):682–7.PubMedGoogle Scholar
  38. 38.
    Alobid I, Mullol J. Role of medical therapy in the management of nasal polyps. Curr Allergy Asthma Rep. 2012;12:144–53.PubMedGoogle Scholar
  39. 39.
    Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, Naclerio RM. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology. 2010;48(3):318–24.PubMedGoogle Scholar
  40. 40.
    Vennera MC, Picado C, Mullol J, Alobid I, Bernal-Sprekelsen M. Efficacy of omalizumab in the treatment of nasal polyps. Thorax. 2011;66(9):824–5.Google Scholar
  41. 41.
    Incorvaia C, Mauro M, Riario-Sforza GG, Frati F, Tarantini F, Caserini M. Current and future applications of the anti-IgE antibody omalizumab. Biologics. 2008;2(1):67–73.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Holgate ST, Djukanovid R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy. 2005;35(4):408–16.PubMedGoogle Scholar
  43. 43.
    Walsh GM. Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions. Curr Opin Mol Ther. 2009;11(3):329–36.PubMedGoogle Scholar
  44. 44.
    Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118(5):1133–41.PubMedGoogle Scholar
  45. 45.
    Blomqvist EH, Lundblad L, Anggard A, Haraldsson PO, Stjarne P. A randomized controlled study evaluating medical treatment versus surgical treatment in addition to medical treatment of nasal polyposis. J Allergy Clin Immunol. 2001;107:224–8.PubMedGoogle Scholar
  46. 46.
    Van Zele T, Gevaert P, Holtappels G, Beule A, Wormald PJ, Mayr S, et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol. 2010;125(5):1069–76.e4.PubMedGoogle Scholar
  47. 47.
    Stevenson DD. Aspirin desensitization in patients with AERD. Clin Rev Allergy Immunol. 2003;24:159–68.PubMedGoogle Scholar
  48. 48.
    Nucera E, Schiavino D, Milani A, et al. Effects of lysine acetyl salicylate (LAS) treatment in nasal polyposis: two controlled long term prospective follow up studies. Thorax. 2000;55:75–8.Google Scholar
  49. 49.
    Ogata N, Darby Y, Scadding G. Intranasal lysine-aspirin administration decreases polyp volume in patients with aspirin-intolerant asthma. J Laryngol Otol. 2007;121:1156–60.PubMedGoogle Scholar
  50. 50.
    Kang SH, Dalcin PTR, Piltcher OB, Migliavacca RO. Chronic rhinosinusitis and nasal polyposis in cystic fibrosis: update on diagnosis and treatment. J Bras Pneumol. 2015;41(1):65–76.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Oomen KP, April MM. Sinonasal manifestations in cystic fibrosis. Int J Otolaryngol. 2012;2012:789572.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Steinke JW, Payne SC, Chen PG, Negri J, Stelow EB, Borish L. Etiology of nasal polyps in cystic fibrosis: not a unimodal disease. Ann Otol Rhinol Laryngol. 2012;121(9):579–86.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Hadfield PJ, Rowe-Jones JM, Mackay IS. A prospective treatment trial of nasal polyps in adults with cystic fibrosis. Rhinology. 2000;38(2):63–5.PubMedGoogle Scholar
  54. 54.
    Henriksson G, Westrin KM, Karpati F, Wikström AC, Stierna P, Hjelte L. Nasal polyps in cystic fibrosis: clinical endoscopic study with nasal lavage fluid analysis. Chest. 2002;121(1):40–7.PubMedGoogle Scholar
  55. 55.
    Crockett DM, McGill TJ, Healy GB, Friedman EM, Salkeld LJ. Nasal and paranasal sinus surgery in children with cystic fibrosis. Ann Otol Rhinol Laryngol. 1987;96(4):367–72.PubMedGoogle Scholar
  56. 56.
    Cepero R, Smith RJ, Catlin FI, Bressler KL, Furuta GT, Shandera KC. Cystic fibrosis--an otolaryngologic perspective. Otolaryngol Head Neck Surg. 1987;97(4):356–60.Google Scholar
  57. 57.
    Nishioka GJ, Cook PR, McKinsey JP, Rodriguez FJ. Paranasal sinus computed tomography scan findings in patients with cystic fibrosis. Otolaryngol Head Neck Surg. 1996;114(3):394–9.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Bengü Çobanoğlu
    • 1
  • Mehmet İmamoğlu
    • 1
  • Luisa Bellussi
    • 2
  1. 1.Medical Faculty, Department of OtorhinolaryngologyKaradeniz Technical UniversityTrabzonTurkey
  2. 2.Medical Faculty, Department of Otorhinolaryngology—Head and Neck SurgeryUniversity of SienaSienaItaly

Personalised recommendations